Cost regulators for the National Health Service in England and Wales are sticking with their initial decision to reject the use of GlaskoSmithKline’s Tyverb and Roche’s Herceptin alongside hormone therapy in certain postmenopausal breast cancer patients. In new draft guidance published this morning (Feb 14) the National Institute for Health and Clinical Excellence says that overall survival benefit from using these drugs alongside aromatase inhibitors (AI) as a first-line treatment for postmenopausal patients whose breast cancer has spread elsewhere in the body remains uncertain.
